BlackRock Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

BlackRock Group’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$769K	Buy	55,655 +4,927	+10%	+$79.1K	﹤0.01%	2229
2016 Q3	$917K	Buy	50,728 +35,749	+239%	+$575K	﹤0.01%	2078
2016 Q2	$215K	Buy	14,979 +762	+5%	+$10.3K	﹤0.01%	2557
2016 Q1	$170K	Buy	14,217 +5,158	+57%	+$54.1K	﹤0.01%	2623
2015 Q4	$121K	Sell	9,059 -329	-4%	-$4.04K	﹤0.01%	2633
2015 Q3	$101K	Buy	+9,388	New	+$103K	﹤0.01%	2705
2015 Q1	–	Sell	-1,401	Closed	-$9K	–	2870
2014 Q4	$9K	Hold	1,401	–	–	﹤0.01%	2855
2014 Q3	$14K	Buy	+1,401	New	+$15K	﹤0.01%	2781

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's LXRX Position: Q4 2016 in Review

BlackRock Group increased its Lexicon Pharmaceuticals (LXRX) stake by 9.7% in Q4 2016, buying an estimated $79.1K and bringing the position to 55,655 shares worth $769K. The position accounts for ﹤0.01% of the portfolio, ranked #2229.

BlackRock Group first reported a position in LXRX in Q3 2014 and has held it in 8 quarters since. The position peaked at $917K in Q3 2016. 146 funds tracked by Wall St. Rank hold LXRX as of Q4 2016.

BlackRock Group held 55,655 shares of Lexicon Pharmaceuticals worth $769K as of Q4 2016.
BlackRock Group bought 4,927 Lexicon Pharmaceuticals shares in Q4 2016, an estimated $79.1K.
Lexicon Pharmaceuticals made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2229 holding.
BlackRock Group first reported a position in Lexicon Pharmaceuticals in Q3 2014 and has held it in 8 quarters since.
BlackRock Group's Lexicon Pharmaceuticals position peaked at $917K in Q3 2016.
146 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.